As global markets navigate a landscape of record-high indexes and robust economic indicators, smaller-cap stocks have been capturing attention with their strong performance relative to larger counterparts. In this environment, identifying hidden opportunities requires a keen eye for companies that exhibit resilience and potential amidst broader market shifts.
|
Name |
Debt To Equity |
Revenue Growth |
Earnings Growth |
Health Rating |
|---|---|---|---|---|
|
Mobile Telecommunications |
NA |
4.98% |
0.14% |
★★★★★★ |
|
Ovostar Union |
0.01% |
10.19% |
49.85% |
★★★★★★ |
|
Impellam Group |
31.12% |
-5.43% |
-6.86% |
★★★★★★ |
|
Tianyun International Holdings |
10.09% |
-5.59% |
-9.92% |
★★★★★★ |
|
Arab Insurance Group (B.S.C.) |
NA |
-59.20% |
20.33% |
★★★★★☆ |
|
Hermes Transportes Blindados |
50.88% |
4.57% |
3.33% |
★★★★★☆ |
|
Arab Banking Corporation (B.S.C.) |
213.15% |
18.58% |
29.63% |
★★★★☆☆ |
|
BOSQAR d.d |
94.35% |
39.99% |
23.94% |
★★★★☆☆ |
|
Wilson |
64.79% |
30.09% |
68.29% |
★★★★☆☆ |
|
A2B Australia |
15.83% |
-7.78% |
25.44% |
★★★★☆☆ |
We’ll examine a selection from our screener results.
Simply Wall St Value Rating: ★★★★★★
Overview: Baida Group Co., Ltd primarily operates department stores in China and has a market capitalization of CN¥3.55 billion.
Operations: Baida Group Ltd generates revenue predominantly from its commodity retail business, amounting to CN¥207.42 million.
Baida Group has shown impressive earnings growth, with a 69.3% increase over the past year, surpassing the Multiline Retail industry’s -6.7%. Despite a yearly earnings decline of 24.7% over five years, recent performance is promising with net income jumping to CN¥131.53 million from CN¥20.81 million compared to last year for the nine months ending September 2024. The company remains debt-free and boasts a price-to-earnings ratio of 28.5x, undercutting the broader CN market’s 34.8x ratio, indicating potential value for investors seeking opportunities in this sector.
-
Unlock comprehensive insights into our analysis of Baida GroupLtd stock in this health report.
-
Examine Baida GroupLtd’s past performance report to understand how it has performed in the past.
Simply Wall St Value Rating: ★★★★★☆
Overview: Guizhou Sanli Pharmaceutical Ltd is involved in the research, development, production, and marketing of pharmaceutical products with a market cap of CN¥5.68 billion.
Operations: Guizhou Sanli Pharmaceutical generates revenue primarily from its pharmaceutical products. The company reported a market cap of CN¥5.68 billion, reflecting its scale in the industry.
